Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07746180 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis

Name: Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis — clinical trial record (NCT07746180)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorChinese PLA General Hospital

Started2026-08-21

View on ClinicalTrials.gov ↗

Amendment history

2026-09-16

Recruitment opened

Chinese PLA General Hospital

193 trials monitored

See 4 trials at risk

This study is an open-label, single-arm, exploratory study designed to evaluate the efficacy and safety of Obinutuzumab beta combined with a rapid-tapering glucocorticoid regimen in patients with new-onset ANCA-associated glomerulonephritis (AAGN).

Trial Details

NCT Number	NCT07746180
Lead Sponsor	Chinese PLA General Hospital
Conditions	ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV)
Enrollment	20 participants
Start Date	2026-08-21
Primary Completion	2028-10-30 (estimated)
Study Completion	2029-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-15